Search research articles
Contact Us
Filters
Showing results (41-50 of 92) with videos related to
Page
of 10
Sort By:
Digestive Diseases (Basel, Switzerland)
|
August 28, 2018
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Belén Beltrán, Marisa Iborra, Esteban Sáez-González, et al.
Gastroenterologia Y Hepatologia
|
July 23, 2018
Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents
Marisa Iborra, Belén Beltrán, Nuria Maroto, et al.
Gastroenterology Report
|
March 27, 2020
Management and outcomes of patients with Crohn's disease with first vs multiple surgeries: results from the PRACTICROHN study
Marisa Iborra, Berta Juliá, Maria Dolores Martín Arranz, et al.
World Journal of Gastroenterology
|
January 7, 2017
Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
Marta Maia Bosca-Watts, Xavier Cortes, Marisa Iborra, et al.
Inflammatory Bowel Diseases
|
July 15, 2017
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Mariam Aguas Peris, Virginia Bosó, Belén Navarro, et al.
Gastroenterologia Y Hepatologia
|
September 13, 2024
Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world
Alejandro Mínguez, Elena Coello, Alejandro Garrido, et al.
Revista Espanola De Enfermedades Digestivas
|
January 29, 2026
Long-term use of subcutaneous infliximab biosimilar CT-P13 in patients with inflammatory bowel disease in clinical practice
José María Huguet, Lidia Martí Romero, Marta Maia Boscá-Watts, et al.
Current Medical Research and Opinion
|
February 7, 2019
Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
Carlos Taxonera, Marisa Iborra, Marta Maia Bosca-Watts, et al.
Gastroenterologia Y Hepatologia
|
April 18, 2025
Spanish Working Group in Crohn's Disease and Ulcerative Colitis (GETECCU) position paper for the management of non-perianal fistulizing Crohn's disease
Iago Rodríguez-Lago, Diego Casas-Deza, Jordi Rimola, et al.
Alimentary Pharmacology & Therapeutics
|
May 5, 2022
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis
Carlos Taxonera, María Jesús Fernández-Aceñero, David Olivares, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 92) with videos related to
Sort By:
Page
of 10
Digestive Diseases (Basel, Switzerland)
|
August 28, 2018
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Belén Beltrán, Marisa Iborra, Esteban Sáez-González, et al.
Gastroenterologia Y Hepatologia
|
July 23, 2018
Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents
Marisa Iborra, Belén Beltrán, Nuria Maroto, et al.
Gastroenterology Report
|
March 27, 2020
Management and outcomes of patients with Crohn's disease with first vs multiple surgeries: results from the PRACTICROHN study
Marisa Iborra, Berta Juliá, Maria Dolores Martín Arranz, et al.
World Journal of Gastroenterology
|
January 7, 2017
Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
Marta Maia Bosca-Watts, Xavier Cortes, Marisa Iborra, et al.
Inflammatory Bowel Diseases
|
July 15, 2017
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Mariam Aguas Peris, Virginia Bosó, Belén Navarro, et al.
Gastroenterologia Y Hepatologia
|
September 13, 2024
Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world
Alejandro Mínguez, Elena Coello, Alejandro Garrido, et al.
Revista Espanola De Enfermedades Digestivas
|
January 29, 2026
Long-term use of subcutaneous infliximab biosimilar CT-P13 in patients with inflammatory bowel disease in clinical practice
José María Huguet, Lidia Martí Romero, Marta Maia Boscá-Watts, et al.
Current Medical Research and Opinion
|
February 7, 2019
Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
Carlos Taxonera, Marisa Iborra, Marta Maia Bosca-Watts, et al.
Gastroenterologia Y Hepatologia
|
April 18, 2025
Spanish Working Group in Crohn's Disease and Ulcerative Colitis (GETECCU) position paper for the management of non-perianal fistulizing Crohn's disease
Iago Rodríguez-Lago, Diego Casas-Deza, Jordi Rimola, et al.
Alimentary Pharmacology & Therapeutics
|
May 5, 2022
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis
Carlos Taxonera, María Jesús Fernández-Aceñero, David Olivares, et al.
Page
of 10